Cipla Limited – an Indian multinational pharmaceutical company, headquartered in Mumbai, India recently launched a testing kit for COVID-19 antibody detection under the brand name “ELIFast”.
Mumbai, India; October 28, 2020: Cipla Limited in partnership with KARWA Limited announced the commercialization, marketing, and distribution of the SARS CoV-2-lgG antibody detection ELISA under the brand name ‘ELIFast’.
ELIFast has been identified and validated by ICMR (Indian Council of Medical Research) and NIV, Pune (National Institute of Virology). The testing kit will be manufactured by KARWA Ltd. and distributed by Cipla Ltd.
ELIFast is helpful in identifying the immune level of individuals to the coronavirus infection. ICMR has recommended these tests for conducting sero-surveillance. Serosurveillance may help in determining the burden of COVID-19 at the community level and monitor the trends in the transmission of SARS-CoV-2 infection.
It is found to have specificity and sensitivity of 99.33% and 92% respectively. The kit is user friendly with a simple protocol with ready-to-use reagents and is compatible with common ELISA equipment.
About CIPLA Limited
Cipla Limited is an Indian multinational pharmaceutical company, headquartered in Mumbai, India. Cipla primarily develops medicines to treat respiratory, cardiovascular disease, arthritis, diabetes, weight control, and depression; other medical conditions.
In July 2020, the company announced the introduction of Gilead Sciences’ Remdesivir under the brand name CIPREMI in India after reaching a voluntary licensing agreement with the parent company and DCGI approval for “restricted emergency use” in COVID-19 treatment of critical confirmed patients.